HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Silence Therapeutics (NASDAQ:SLN) and maintained a $75 price target.
June 20, 2024 | 3:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Silence Therapeutics (NASDAQ:SLN) and maintained a $75 price target.
The reiteration of a Buy rating and the maintenance of a $75 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100